Ditchcarbon
  • Contact
  1. Organizations
  2. Evotec
Public Profile
Pharmaceutical Preparation Manufacturing
DE
updated a month ago

Evotec

Company website

Evotec SE, a leading global biotechnology company headquartered in Germany, is renowned for its innovative drug discovery and development solutions. Founded in 1993, Evotec has established a strong presence in Europe, North America, and Asia, focusing on areas such as central nervous system disorders, metabolic diseases, and oncology. The company offers a unique platform that integrates cutting-edge technologies and extensive expertise, enabling efficient and effective drug development processes. Notable achievements include strategic partnerships with major pharmaceutical firms, positioning Evotec as a key player in the biopharmaceutical industry. With a commitment to advancing healthcare, Evotec continues to drive progress in the development of novel therapeutics, making significant contributions to the global fight against disease.

DitchCarbon Score

How does Evotec's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

85

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Evotec's score of 85 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.

91%

Let us know if this data was useful to you

Evotec's reported carbon emissions

In 2024, Evotec SE reported total greenhouse gas emissions of approximately 300,670,000 kg CO2e. This includes 15,937,000 kg CO2e from Scope 1 emissions, 11,672,000 kg CO2e from Scope 2 (market-based), and a significant 273,060,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 185,479,000 kg CO2e. Evotec has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 GHG emissions by 50.4% from a 2021 base year by 2032. Additionally, the company plans to achieve a 95% reduction in these emissions by 2045. For Scope 3 emissions, Evotec targets a 72% reduction from purchased goods and services and capital goods by 2032, with a long-term goal of reducing these emissions by 97% per million EUR value added by 2045. The company is also committed to increasing its sourcing of renewable electricity from 25% in 2021 to 100% by 2026, maintaining this level through 2030. Furthermore, Evotec aims for 80% of its suppliers, by emissions, to have science-based targets by 2027. These targets align with the Science Based Targets initiative (SBTi) and reflect Evotec's commitment to achieving net-zero emissions across its value chain by 2045.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201920202021202220232024
Scope 1
28,000
00,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Evotec's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Evotec is in DE, which has a medium grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Evotec is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Bruker Cellular Analysis, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Cambrex Karlskoga

SE
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Pharmaceutical Product Development, LLC

US
•
Research and development services (73)
Updated 24 days ago

Thermo Fisher Scientific

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 14 hours ago

Orion

FI
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Novartis

CH
•
Pharmaceutical Preparation Manufacturing
Updated about 4 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251007.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy